title: Hepatitis A: epidemiology in resource-poor countries.
abstract: OBJECTIVE
  Transmission of hepatitis A virus (HAV) infection is primarily fecal-oral. Symptomatic hepatitis, severe disease, and death are more likely to occur when infection occurs at an older age. Improvements in socioeconomic and hygienic conditions have led to a change in its epidemiology worldwide.
  
  
  RESULTS
  In the last two decades, improved hygiene in several resource-poor countries has led to reduced transmission of HAV, an increase in average age at infection, and, consequently, a paradoxical increase in morbidity and mortality because of hepatitis A. In Argentina, introduction of one dose (instead of the conventional two doses, to reduce costs) of inactivated HAV vaccine at 12-month age in a universal childhood immunization program during such 'epidemiologic transition' has markedly reduced the incidence of symptomatic hepatitis A, and of fulminant hepatitis and liver transplantation caused by HAV infection. The monetary value of medical and nonmedical benefits of this strategy outweighed the expenditure on vaccination. These excellent results were possibly contingent upon a high vaccination coverage.
  
  
  CONCLUSIONS
  Resource-poor countries should closely monitor the epidemiology of HAV infection and periodically undertake cost-effectiveness analyses of HAV immunization strategies. This should allow timely identification of epidemiologic transition and introduction of preventive strategies before HAV infection becomes a public health problem.
authors.affiliation: Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Aggarwal
authors.forename: Amit
authors.initials: A
authors.lastname: Goel
mesh_terms: D003362:Cost-Benefit Analysis; D003906:Developing Countries; D006506:Hepatitis A / Q000191:economics / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D022362:Hepatitis A Vaccines; D006801:Humans; D017589:Immunization Programs
chemical_list: D022362:Hepatitis A Vaccines